Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled trial of CIM331 in atopic dermatitis with inadequate response to topical therapy
2013-002470-46Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing CIM331 arm with Placebo arm (2 arms). Primary endpoint: Percent improvement from baseline in pruritus VAS at Week 12. Started Sep 2013; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2013-002470-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002470-46.